Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $2.6 million.

  • Cartesian Therapeutics' Share-based Compensation rose 5280.24% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year decrease of 4569.75%. This contributed to the annual value of $6.6 million for FY2024, which is 7077.78% down from last year.
  • Per Cartesian Therapeutics' latest filing, its Share-based Compensation stood at $2.6 million for Q3 2025, which was up 5280.24% from $3.3 million recorded in Q2 2025.
  • Cartesian Therapeutics' Share-based Compensation's 5-year high stood at $14.1 million during Q4 2023, with a 5-year trough of $1.4 million in Q1 2024.
  • In the last 5 years, Cartesian Therapeutics' Share-based Compensation had a median value of $2.3 million in 2022 and averaged $3.0 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 52144.11% in 2023, then plummeted by 8681.42% in 2024.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Share-based Compensation stood at $2.3 million in 2021, then grew by 1.02% to $2.3 million in 2022, then soared by 521.44% to $14.1 million in 2023, then crashed by 86.81% to $1.9 million in 2024, then surged by 38.87% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $3.3 million for Q2 2025, and $2.5 million during Q1 2025.